Roche (RHHBY) has hired a senior executive from Novo Nordisk (NVO) as it prepares to enter the competitive market for obesity drugs, Bloomberg’s Naomi Kresge and Sara Sjolin report. Morten Lammert will join Roche as its global therapeutic area head for cardiovascular, renal and metabolism, a new role, on June 1, a spokesman says. Lammert had served as corporate vice president for obesity strategy and projects at Novo Nordisk.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech receives FDA acceptance for Gazyva sBLA
- Genentech announces FDA approval of TNKase in acute ischemic stroke
- Roche’s Genetech announces data from Phase III OUtMATCH study
- Roche says CHMP recommends EU approval of Columvi combination
- Roche SBX announcement creates more uncertainty for Illumina, says RBC